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Abstract
Background Since 1983 four consecutive unified regi-
mens: acute myeloid leukemia-Polish pediatric leu-
kemia/lymphoma study group (AML-PPLLSG) 83, 
AML-PPLLSG 94, AML-PPLLSG 98 and AML-BFM 2004 
Interim, for AML have been conducted by the Polish 
Pediatric Leukemia/Lymphoma Study Group (PPLLSG). 
In this paper, we review four successive studies on the 
basis of acute myeloid leukemia-Berlin–Frankfurt–Mun-
ster (AML-BFM) protocol, in which a stepwise improve-
ment of treatment outcome was observed. Treatment 
results of the last protocol AML-BFM 2004 Interim are 
presented in detail.
memo (2013) 6:54–62
DOI 10.1007/s12254-012-0061-9
Development of treatment and clinical results  
in childhood acute myeloid leukemia in Poland
Walentyna Balwierz, Katarzyna Pawinska-Wasikowska, Tomasz Klekawka,  
Malgorzata Czogala, Michal Matysiak, Barbara Fic-Sikorska, Elzbieta Adamkiewicz-Drozynska,  
Lucyna Maciejka-Kapuscinska, Alicja Chybicka, Kinga Potocka, Jacek Wachowiak,  
Jolanta Skalska-Sadowska, Jerzy Kowalczyk, Beata Wojcik, Mariusz Wysocki, Sylwia Koltan, 
Maryna Krawczuk-Rybak, Katarzyna Muszynska-Roslan, Wojciech Mlynarski, Malgorzata Stolarska, 
Tomasz Urasinski, Elzbieta Kamienska, Tomasz Szczepanski, Renata Tomaszewska, Grazyna Sobol, 
Agnieszka Mizia-Malarz, Grazyna Karolczyk, Joanna Podhorecka, Maria Wieczorek,  
Irena Karpinska-Derda, Wanda Badowska, Angelina Moryl-Bujakowska
Prof. W. Balwierz, MD () · T. Klekawka, MD, PhD · 
M. Czogala, MD, PhD · K. Pawinska-Wasikowska, MD, PhD · 
A. Moryl-Bujakowska, MD, PhD
Pediatric, Oncology and Hematology Department, PA Institute of 
Pediatrics, Jagiellonian University Medical College, ul. Wielicka 
265, 30-663-Krakow, Poland
e-mail: balwierz@mp.pl, walentyna@balwierz.com
Prof. M. Matysiak, MD, PhD · B. Fic-Sikorska, MD, PhD
Department of Pediatrics, Hematology and Oncology, Medical 
University, Warsaw, Poland
Prof. E. Adamkiewicz-Drozynska, MD, PhD ·  
L. Maciejka-Kapuscinska, MD, PhD
Department of Pediatrics, Hematology, Oncology and 
Endocrinology, Medical University of Gdansk, Gdansk, Poland
Prof. A. Chybicka, MD, PhD · K. Potocka, MD
Department of Pediatric Transplantology, Oncology and 
Hematology, Medical Academy of Wroclaw, Wroclaw, Poland
Prof. J. Wachowiak, MD, PhD · J. Skalska-Sadowska, MD
Department of Pediatric Oncology, Hematology and 
Transplantology, University of Medical Sciences, Poznan, Poland
Prof. J. Kowalczyk, MD, PhD · B. Wojcik, MD, PhD
Department of Hematology and Oncology, Medical University, 
Lublin, Poland
Prof. M. Wysocki, MD, PhD · S. Koltan, MD, PhD
Department of Pediatrics, Hematology and Oncology,  
Institute of Pediatrics, Medical Academy, Bydgoszcz, Poland
Received: 15 August 2012 / Accepted: 31 October 2012 / Published online: 21 December 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com 
Prof. M. Krawczuk-Rybak, MD, PhD ·  
K. Muszynska-Roslan, MD, PhD
Department of Pediatric, Hematology and Oncology, Medical 
University, Bialystok, Poland
Prof. W. Mlynarski, MD, PhD · M. Stolarska, MD, PhD
Department of Pediatrics, Hematology, Oncology and 
Endocrinology, Medical University, Lodz, Poland
T. Urasinski, MD, PhD · E. Kamienska, MD, PhD
First Department of Pediatrics, Pomeranian Medical Academy, 
Szczecin, Poland
Prof. T. Szczepanski, MD, PhD · R. Tomaszewska, MD, PhD
Department of Pediatric, Hematology and Oncology, Silesian 
Medical University, Katowice, Poland
G. Sobol, MD, PhD · A. Mizia-Malarz, MD, PhD
Oncology and Hematology Unit of Pediatric Department,  
Silesian Medical University, Katowice, Poland
G. Karolczyk, MD · J. Podhorecka, MD, PhD
Oncology and Hematology Unit of Pediatric Hospital, Kielce, 
Poland
M. Wieczorek, MD, PhD · I. Karpinska-Derda, MD, PhD
Pediatrics and Oncology Center, Chorzow, Poland
W. Badowska, MD, PhD
Oncology and Hematology Unit of Pediatric Hospital,  
Olsztyn, Poland
review
Development of treatment and clinical results in childhood acute myeloid leukemia in Poland  551 3
Methods Three hundred and three patients with de novo 
AML were treated according to the AML-BFM 2004 In-
terim at 15 Polish centers from January 1, 2005 to June 
30, 2011. A confrontation with previous treatment peri-
ods was based upon historical, already published data.
Results In four consecutive periods, 723 children were 
eligible for evaluation (208, 83, 195, and 237, respec-
tively). Complete remission rates in consecutive periods 
were: 71, 68, 81 and 87 %, respectively. The 5-year over-
all survival rates, event-free survival rates, and relapse-
free survival rates were 33, 32, and 45%, respectively for 
AML-PPLLSG 83 regimen; 38, 36, and 53 % respectively 
for AML-PPLLSG 94 regimen; 53, 46, and 65  % respec-
tively for AML-PPLLSG 98 regimen, and 63, 52, and 64 % 
for AML–BFM Interim 2004, respectively. Incidence of 
early deaths and that due to complications (mainly in-
fections) in the first remission decreased over time from 
22 to 4.6 % and from 10 to 5.9 %, respectively.
Conclusions Despite continuous improvement in the 
treatment outcome, the number of failures still remains 
too high. Further progress seemed to be possible due to 
continued cooperation of oncology centers within large 
international study groups.
Keywords: Acute myeloid leukemia, Children, Treat-
ment results
Introduction
In 1983, the Polish Pediatric Leukemia/Lymphoma Study 
Group (PPLLSG) introduced, for acute myeloid leukemia 
(AML) treatment, a unified AML-PPLLSG 83 treatment 
protocol, which was a modified version of Berlin–Frank-
furt–Munster (BFM)-AML 83 protocol. Our goal was to 
test the feasibility of this intensive protocol in our con-
ditions, and to develop nationwide diagnostic and treat-
ment standards. This new protocol improved the cure 
rate for AML from 15 % to approximately 32 %, which was 
a remarkable progress, however our results were still sig-
nificantly worse compared to the original acute myeloid 
leukemia-Berlin–Frankfurt–Munster (AML-BFM) proto-
col [1–4]. The lower remission rate due to a large num-
ber of early deaths was one of the main reasons for 
treatment failure. High number of toxicities, especially 
due to problems with sufficient supportive care, made 
us very cautious about introduction of high-dose cyta-
rabine. Therefore, in our further protocols, we decided 
not to follow the AML-BFM protocol strictly (but to keep 
its backbone). In 1994, a modification of AML-PPLLSG 
83 protocol was made: the high-risk patients (≥ 5  % 
blasts in bone marrow on day 15 of therapy and all M5 
cases) received two additional cycles with intermediate-
dose cytarabine (ID-ARAC). This led to an insignificant 
increase in event-free survival (EFS) rate from 32 to 36 %. 
However, the ID-ARAC courses were not effective in pro-
ducing remissions in late responders and remission rate 
did not increase [3, 5].
In our next AML-PPLLSG 98 protocol, we tried to 
develop a better and more useful stratification system. As 
several reports stated high activity of a new drug—ida-
rubicin—in producing remissions we also decided to 
introduce it to our protocol [6–8], which resulted in bet-
ter initial responses. Moreover, an increase in complete 
remission (CR) after induction therapy and the number 
of patients in standard risk group (SR) were observed. 
Unsatisfactory treatment outcome in the high-risk (HR) 
group children was mainly caused by the low remis-
sion rate [3, 9]. In 2005, by courtesy of Prof. U. Creutzig, 
the AML-BFM 2004 Interim protocol was introduced in 
PPLLSG centers for further improvement of results of 
childhood AML treatment.
In this paper, data from the last treatment period are 
presented. A confrontation with previous treatment 
periods is based upon already published data [3, 9]. In 
three historical periods AML-PPLLSG 83 (1983–1993), 
AML-PPLLSG 94 (1994–1997), and AML-PPLLSG 98 
(1998–2004), 575 children were enrolled (226, 102, 247, 
respectively) and 486 of them were eligible for evalua-
tion (208, 83, 195, respectively)—Table  3. Observations 
for those periods were completed on March 31, 2002, for 
AML-PPLLSG 83 and AML-PPLLSG 94 protocols and on 
November 30, 2008 for AML-PPLLSG 98.
Elements of four consecutive treatment protocols and 
classification criteria for the risk groups are presented in 
Tables 1 and 2.
Materials and methods
Three hundred and three children with de novo AML 
treated according to AML-BFM-2004 Interim protocol 
were enrolled at 15 PPLLSG centers; 237 of them were eli-
gible for evaluation from January 2005 to June 2011. The 
exclusion criteria were:
•	 	AML	 following	 chronic	myeloid	 leukemia	 or	myelo-
dysplastic syndrome,
•	 	AML	as	a	secondary	neoplasm,
•	 	congenital	 malformations	 and	 severe	 comorbidities	
(including Down’s syndrome),
•	 	biphenotypic	leukemia,
•	 	death	before	treatment,
•	 	pretreatment	with	other	protocols	or	incomplete	data	
of the patient.
The inclusion criteria were:
•	 	‘de	novo’	diagnosed,
•	 	untreated	AML,
•	 	absence	 of	 severe	 congenital	 malformations	 or	
comorbidities.
Data regarding children with Down’s syndrome and AML 
will be presented in another paper. In all children, the 
diagnosis was based upon bone marrow (BM) examina-
tion, including cell morphology with FAB classification, 
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cytochemistry, and immunophenotyping. Complete 
blood count, liver and renal function tests, lumbar punc-
ture, chest X-ray, echocardiography (ECG) and brain 
computed tomography (CT) were also performed in 
all children. Cytogenetic analyses (both classical and 
fluorescence in situ hybridization (FISH)) were also 
mandatory, nevertheless, only the results from 74  % of 
patients were eligible. All examinations were performed 
in local treatment centers. Since 2005 central verification 
sessions of cell morphology, immunophenotyping and 
cytogenetic examination have been made. Moreover, 
since 2006 molecular studies (fusion genes AML1-ETO, 
Table 1 Treatment elements of the four consecutively used treatment protocols
AML-PPLLSG 83 AML-PPLLSG 94 AML-PPLLSG 98 AML-BFM 2004 Interim
SRG and HRG SRG and HRG SRG and HRG
1983–1993 1994–1997 1998–2004
Induction phase
Induction ADE Induction ADE Induction AIE (idarubicin adminis-
tered on days: 3, 4 and 5)
Induction AIE (idarubicin administered on 
days: 3, 5 and 7)
Consolidation phase
Consolidation phase 1A: 4-weeks Consolidation phase 1A: 4 week 
consolidation phase: as a second ele-
ment in SR and as a fourth element 
in HR
Consolidation phase 1A: 4-week 
consolidation phase: as a second 
element in SR and as a fourth 
element in HR idarubicin instead of 
daunorubicin
SRG: AI chemotherapy
HRG: HAM (second induction chemo-
therapy), AI chemotherapy
Consolidation phase 1B: 4 weeks Consolidation phase 1B: Only in SRG Consolidation phase 1B:
only in SRG
SRG and HRG: haM
HRG: intermediate cytarabine doses + 
daunorubicin
HRG: intermediate cytarabine doses 
+ idarubicin
Intensification phase 1
HRG: Intermediate cytarabine doses
etoposide
Intensification phase 1
Intermediate cytarabine doses
etoposide
HAE chemotherapy
Intensification phase 2
HRG: two-week treatment with: 
cytarabine, 6-thioguanine and cyclo-
phosphamide
Intensification phase 2
HRG: two-week treatment with: 
cytarabine, 6-thioguanine and  
cyclophosphamide
Cranial irradiaton
During consolidation phase 1B 
doses: < 1 year = 12 Gy, 1–2 years 
= 15 Gy, > 2 years = 18 Gy
SRG: timing and doses as before
HRG: during intensification phase 2, 
doses as before
SRG and HRG: as in previous pro-
tocol, but no irradiation in children 
< 1 year
SRG and HRG: parallelly to beginning of 
maintenance therapy, doses: < 15 months 
= no irradiation, 15 to < 24 months 
= 15 Gy, ≥ 24 months = 18 Gy
Intrathecal treatment
During consolidation phase 1B: 
cytarabine on days 31, 38, 45, 
51, dose adjusted to age: < 1year 
= 20 mg, 1–2 years = 26 mg, 2–3 
years = 34 mg, > 3 years = 40 mg
SRG: cytarabine, timing and doses 
as before; HRG: cytarabine, timing 
and doses as before and additional 
doses during blocks: Intermediate 
cytarabine doses + daunorubicine, 
Intermediate cytarabine doses + 
etoposide and Intensification phase 2, 
day 1, 8, and 15
SRG: as in previous protocol and 
additional Cytarabine dose during 
AIE on day 3 and 7; HRG: as in SRG 
during induction and consolidation 
1A blocks; further treatment as in 
previous protocol; cytarabine doses 
as in previous protocols
SRG and HRG—during chemotherapy 
blocks: AIE—days 1 and 8
AI—days 1 and 6
haM—days 0 and 6
HAE—day 0; HRG: additionally during 
HAM chemotherapy block—day 0.
SRG and HRG—during maintenance 
treatment parallelly to CNS irradiation 
four times during first 4 weeks, one time 
per week; cytarabine doses as in previous 
protocols
Maintenance treatment
Maintenance treatment: 6-Thio-
guanine + cytarabine pulses, up to 
2 years of total therapy
SRG: 6-thioguanine + cytarabine 
pulses, up to 2 years of total therapy; 
HRG: 6-thioguanine + cytarabine 
pulses, up to 1 year of total therapy
SRG: 6-thioguanine + cytarabine 
pulses, up to 2 years of total therapy; 
HRG: 6-thioguanine + cytarabine 
pulses, up to 1 year of total therapy
SRG and HRG: 6-thioguanine + cytarabine 
pulses, up to 1 year of total therapy
Stem cell transplantation
Not given (very limited access) SRG and HRG: recommended but 
limited access
SRG: not recommended; HRG: 
recommended
Allogeneic HSCT from an HLA-identical 
sibling donor is indicated for all HRG 
patients, other indications—as described 
in present paper
A cytarabine, AML-BFM acute myeloid leukemia-Berlin–Frankfurt–Munster, AML-PPLLSG  acute myeloid leukemia-Polish pediatric leukemia/lymphoma study 
group, D daunorubicine, E etoposide, haM intermediate cytarabine doses + mitoxanthrone, HAM high cytarabine doses + mitoxanthrone, HLA human leukocute 
antigen, HRG high-risk group, HSCT hematopoietic stem cell transplantation, I idarubicine, M mitoxanthrone, SRG standard-risk group
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PML-RARA, CBFβ-MYH11 and MLL–AF4, MLL–AF9, 
MLL–ENL, as well as FLT3-ITD and WT1 overexpression) 
have also been performed in Genetic Laboratory of the 
University Children’s Hospital of Krakow.
Elements of AML-BFM 2004 Interim treatment pro-
tocol and classification criteria for risk groups are pre-
sented in Tables  1 and 2. According to AML-BFM 2004 
Interim protocol allogeneic hematopoietic stem cell 
transplantation (allo-HSCT) from HLA-identical sibling 
donor was indicated in all patients of the HR group in 
the first remission. Children with blasts after the second 
induction (HAM) or still in aplasia 4 weeks after second 
induction were qualified for allo-HSCT from an human 
leukocyte antigen (HLA)-identical unrelated donor.
Supportive care guidelines include the use of prophy-
lactic antifungal medication and co-trimoxazole/trime-
thoprim against Pneumocystis jiroveci in all patients. We 
do not use hematopoietic growth factors (such as G-CSF) 
or antibiotics routinely as a prophylaxis regimen.
Treatment toxicity analysis was not performed because 
of insufficient data received by the time of preparation 
of this paper. Patients’ characteristics are presented in 
Table 3.
Complete remission was defined as no more than 5 % 
of blasts in BM demonstrating normal or only slightly 
decreased cellularity with signs of regeneration of nor-
mal hematopoiesis, regeneration of normal cell pro-
duction in peripheral blood, lack of blasts in peripheral 
blood and disappearance of any extramedullary sites.
Treatment failures classified according to criteria pro-
posed by Creutzig et al. [10], included:
•	 	Early	death—defined	as	death	during	the	first	42	days	
from the start of the treatment.
•	 	Death	in	continuous	CR—treatment	related	mortality	
(TRM), including death after HSCT in the first CR.
•	 	Nonresponder—defined	as	a	lack	of	CR	during	6	weeks	
since the start of the treatment.
•	 	Relapses.
For patients who completed consolidation while still 
having active disease, second-line protocols were 
recommended.
The results were expressed by means of remission 
rates, EFS, overall survival (OS), and relapse-free survival 
(RFS). Survival rates were analyzed using the Kaplan–
Meier method and compared with the log-rank test. For 
statistical analyses, STATISTICA, version 10, StatSoft Inc. 
(2011) software packages were used. The observation was 
completed on November 30, 2011.
Results of treatment
Treatment results are presented in Tables  4–5 and 
Figs. 1–7.
Out of 237 children eligible for evaluation, treated 
according to AML-BFM Interim 2004, 66 (28  %) were 
stratified into SR group and 171 (72 %) into HR group. CR 
was achieved in 207 (88 %) children. Eighty-one children 
died, 11 before day 42 of the induction therapy (early 
deaths) and 14 children in remission (3 patients after allo-
HCST). Ten CR patients died because of severe infections 
and one died from CNS toxicity that developed probably 
after cytarabine. Results of BM aspiration biopsy done on 
day 15 were available in 216 children with 56 (26 %) dem-
onstrating more than 5 % of blasts in BM. Five year OS, 
EFS, and RFS for all evaluated children were 63 ± 3, 52 ± 3 
and 64 ± 4 %, respectively (Fig. 1). OS and EFS rates were 
comparable in both risk groups (SR: 69 ± 6 and 55 ± 7 %, 
respectively, HR: 61 ± 4 and 50 ± 4 %, respectively). How-
ever, neither of those results were statistically significant 
(Figs. 2 and 3). In patients who eventually relapsed, CR 
lasted from 0.86–46.7 months (median: 10.5 months).
For the entire evaluated group, significant impact of 
initial WBC count on treatment outcome (EFS and RFS) 
was demonstrated (p = 0.026 and 0.003, respectively). 
WBC count is defined as high if it is ≥ 20 × 109/L, and 
low if < 20 × 109/L. The highest rates of 5-year EFS and 
RFS were achieved for children with initial WBC count 
< 20 × 109/L. For the entire analyzed group (Table 5), the 
correlation between types of FAB and OS was close to 
statistical significance (p = 0.07), and the worst outcome 
was demonstrated for M5 type (OS = 44 ± 9  %). In the 
HR group the statistical analysis revealed a significant 
impact of initial WBC count on RFS (p = 0.021). The high-
est rate of RFS was seen in children with an initial WBC 
count of < 20 × 109/L. There was no significant impact of 
FAB types on survival rates in the HR group, however the 
lowest rates were obtained for M5 type (OS = 43.9 ± 8.7, 
EFS = 31.3 ± 8.4, RFS = 42.9 ± 10.5). Among 171 children 
stratified into HR group, HSCT in the first CR was per-
formed in 44. Higher survival rates in these patients were 
Study Risk group Definition
AML-PPLLSG 83 No risk group stratification
AML-PPLLSG 94 SR FAB other than M5 and ≤ 5 % blasts in BM 
on day 15
HR GRG M5 and ≤ 5 % blasts in BM on day 15
HR PRG Any FAB and > 5 % blasts in BM on day 15
AML-PPLLSG 98 SR FAB other than M5 and ≤ 5 % blasts in BM 
on day 15 and no increase in blasts count 
after day 15
HR Patients not qualified to SR
AML-BFM 2004 
Interim
SR M1/M2 with Auer rodsa,b AML with 
t(8;21)a,b M4Eo with inv16a,b M3 AML in 
Down’s syndrome
HR M0 M1/M2 without Auer rods M4, M5, 
M6, M7
AML-BFM acute myeloid leukemia-Berlin–Frankfurt–Munster, AML-PPLLSG 
acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group, 
GRG good response group, PRG poor response group, HR high risk,  
SR standard risk, FAB French–American–British
aIn case of FLT3-ITD, the patient is reclassified to HRG
bIn case of blasts are ≥ 5 % on day 15 or blastic reconstitution between 
day15 and 28 (modification according to PPLLSG) the patient is reclassified 
to HRG
Table 2 Risk group definitions
review
58  Development of treatment and clinical results in childhood acute myeloid leukemia in Poland 1 3
observed in comparison with patients from the HR group 
without HSCT (Figs.  4 and 5). The differences were not 
statistically significant.
None of the analyzed factors had relevant influ-
ence on the survival rates in the SR group. The worse 
outcome was in patients with translocation t(8;21) 
(OS = 46 ± 14  %, EFS = 43 ± 13  %, RFS = 46 ± 14  %) in com-
parison with patients without translocation (OS = 66 ± 9 %, 
EFS = 60 ± 9 %, RFS = 66 ± 9 %), although differences were 
not statistically significant (Figs. 6 and 7). In the SR group 
without t(8;21) only one patient demonstrated an inv(16).
Discussion
Since 1983, PPLLSG has introduced four consecutive uni-
fied protocols for the treatment of AML: AML-PPLLSG 83, 
AML-PPLLSG 94, AML-PPLLSG 98, and AML-BFM 2004 
Interim. Therapies based on AML-BFM protocols have 
led to a gradual increase of the 5-year EFS from less than 
15 % before 1983, to 52 % after 2004 (Table 4). Within the 
last 25 years we observed a progressive increase of OS 
from 33 to 65  %. Treatment failure rates have decreased 
gradually, but still remain our major concern. Total early 
deaths decreased from 22 % in the first period to 4.2 % in 
Table 3 Patient characteristics in four AML treatment protocols in Poland
Parameters AML-PPLLSG 83 AML-PPLLSG 94 AML-PPLLSG 98 AML-BFM 2004 Interim
1983–1994 1994–1997 1998–2004 2005–2011
[3] [3] [9]
Number of patients (N) 208 83 195 237
Age (years) median 8.3 9.3 8.5 11.2
Q1–Q3 4.3–15.3
Range 0.1–16.6 0.6–16.6 0.1–17.8 0.006–18.1
Leukocytes (× 103/µl) median 12.0 14.7 17.8 19.4
Q1–Q3 ND ND ND 6.1–58.8
Range 0.6–264 1.0–587 0.5–516 0.76–979
Gender male/female 106/102 40/43 105/95 130/107
N (%) N (%) N (%) N (%)
CNS involvementa 10 (4.9) 5 (6.3) 7 (3.6) 29/206 (14.1)
Extramedullary organ involve-
ment
44 (21) 16 (19) 31 (15.9) 60/206 (29.1)
FAB types
M0 0 (0.0) 3 (3.6) 15 (7.7) 21 (8.9)
M1 43 (20.7) 12 (14.5) 32 (16.4) 32 (13.5)
M2 53 (25.5) 24 (28.9) 55 (28.2) 66 (27.8)
M3 23 (11.1) 9 (10.8) 23 (11.8) 20 (8.4)
M4 50 (24.0) 18 (21.7) 30 (15.4) 48 (20.3)
M5 30 (14.4) 11 (13.3) 18 (9.2) 36 (15.2)
M6 8 (3.8) 3 (3.6) 7 (3.6) 3 (1.3)
M7 1 (0.5) 1 (1.2) 8 (4.1) 10 (4.2)
Non defined 0 (0.0) 2 (2.4) 7 (3.6) 1 (0.4)
Cytogenetic availablea 0 (ND) 54 (65) 37 (19.0) 176 (74)
t(8;21) 2 3 26 (15)
t(15;17) 0 3 16 (9)
inv(16) 1 0 8 (4.5)
Normal 18 10 30 (17)
MLL ND ND 15 (8.5)
Other 11 21 81 (46)
Risk groups
SR NA 36 (43) 112 (57) 66 (27.8)
HR NA 39 (47) 69 (36) 171 (72.2)
Non qualified NA 8 (10) 14 (7) 0 (0)
AML-BFM acute myeloid leukemia-Berlin–Frankfurt–Munster, AML-PPLLSG  acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group, NA  not 
applicable, ND not defined, acute myeloid leukemia
aPercentage is given for patients with data (n/total)
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Fig. 1 Overall survival (OS), event-free survival (EFS) and 
relapse-free survival (RFS) for a total group of children with 
acute myeloid leukemia treated according to AML-BFM 2004 
Interim protocol in Poland
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  5-year OS = 63.1 ± 3.3% (N=237. 81 deaths)
  5-year EFS = 51.8 ± 3.5% (N=237. 107 events)
  5-year RFS = 64.4 ± 3.7% (N=207. 64 relapses)
Fig. 2 Overall survival (OS) for two risk groups of children 
with acute myeloid leukemia treated according to AML-BFM 
2004 Interim protocol in Poland
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SR group: 5-year OS = 69 ± 6% (N=66. 22 deaths)
HR group: 5-year OS = 61 ± 4% (N=171. 63 deaths)
Log-rank test: p=0.12
Fig. 3 Even-free survival (EFS) for two risk groups of children 
with acute myeloid leukemia treated according to AML-BFM 
2004 Interim protocol in Poland
SR group: 5-year EFS=55 ± 7% (N=66. 27 events)
HR group: 5-year EFS=50 ± 4% (N=171. 80 events)
Log-rank test: p=0.22
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Fig. 4 Overall survival (OS) for HR group with and without 
HSCT in first remission treated according to AML-BFM 2004 
Interim protocol in Poland
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Log-rank test: p=0.208
HR group with HSCT
5-year OS = 75.8 ± 6.7% (N=44. 10 deaths)
HR group without HSCT
5-year OS = 64.5 ± 5.1% (N=102. 33 deaths)
            
Fig. 5 Event-free survival (EFS) for HR group with and without 
HSCT in first remission treated according to AML-BFM 2004 
Interim protocol in Poland
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Log-rank test: p=0.13
HR group with HSCT
5-year EFS=61.5 ± 7.2% (n=44. 13 events)
HR group without HSCT
5-year EFS=68.5 ± 7.3% (n=102. 42 events)
Fig. 6 Overall survival (OS) for children in SR group of acute 
myeloid leukemia with and without the presence of t(8;21) 
treated according to AML-BFM 2004 Interim protocol in 
Poland
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Log-rank test: p=0.26
t (8;21) negative group: 4-year OS=79 ± 7% (N=35. 7 deaths) 
t (8;21) positive group: 4-year OS=52 ± 15% (N=15. 6 deaths) 
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the fourth period. Deaths in remission decreased from 
10 % in the first and the second period to 5.9 % in a current 
protocol. Number of non-responders increased between 
the first and the second period from 6 to 18 %, and then 
decreased to 8.5 % at present. Observed reductions of early 
death and treatment-related mortality were achieved by 
intensification of antileukemic treatment and improve-
ment in supportive care, which also shown in other publi-
cations [10–14]. Experience accumulated for over 30 years 
of using AML-BFM protocols was also of importance.
Some researches in childhood AML have identified 
several prognostic factors. Nowadays genetic abnormali-
ties and response to treatment are considered the most 
relevant factors [14–16]. Significance of other factors, 
such as age, WBC, and FAB type has been not clearly 
verified yet [17, 18]. In our study, statistical analysis of all 
patients revealed that differences for both RFS and EFS 
were significant depending on the initial WBC count and 
close to statistical significance for the FAB type (Table 5). 
We also found statistically significant difference in RFS 
for HR patients depending on the initial WBC (p = 0.021). 
Thus, more detailed analyses are planned to identify the 
exact initial leukocyte count and FAB type responsible for 
a higher risk of treatment failures.
Since 1989, the HSCT has become available in our 
country, but access to this procedure was very limited 
till the late 1990s. In AML-BFM 2004 Interim protocol we 
perform allo-HSCT in patients with unfavorable risk fac-
tors. However, the benefit of allo-HSCT as a post-remis-
sion consolidation treatment in the first remission of 
AML in children remains controversial. The significantly 
lower relapse rate after allo-HSCT is not always fol-
lowed by improvement of survival [19–23]. In our study, 
3 children out of 44 with allo-HSCT in first CR had died 
because of treatment-related death.
About 80–90 % of children with AML achieve CR with 
current protocols, although in around 30 % of them there 
is eventually a relapse [10–14]. Results of therapy for recur-
rent AML remain poor [24, 25]. We are concerned about 
the high event rate in children from the SR group (Fig. 3). 
In this group, lower survival rates were found in patients 
            
Fig. 7 Event-free survival (EFS) for children in SR group 
of acute myeloid leukemia with and without the pres-
ence of t(8;21) treated according to AML-BFM 2004 Interim 
protocol in Poland
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Log-rank test: p=0.23
t (8;21) negative group: 4-year EFS = 60 ± 9% (N=35. 12 events) 
t (8;21) positive group: 4-year EFS = 43 ± 13% (N=15. 8 events) 
Table 4 Treatment results of patients according to AML-BFM 2004 Interim protocol compared to earlier studies in Poland
AML treatment protocols
Parameters AML-PPLLSG 83 AML-PPLLSG 94 AML-PPLLSG 98 AML-BFM 2004 INTERIM
1983–1994 1994–1997 1998–2004 2005–2011
[3] [3] [9]
N (%) N (%) N (%)e N (%)
No. of patients 208 83 195 237
Early death 46 (22.1) 12 (15.1) 16 (8.0) 11, including in M3-3 and M5-4 (4.2)
Blasts day 15 ≥ 5 %a ND 34/72 (47.2) 47/182 (25.6) 56/216 (25.9)
Nonresponders 13 (5.7) 15 (18.0) 20 (10.3) 19 (8.5)
CR achieved 150 (71.4) 56 (67.5) 159 (82.0) 207 (87.3)
Death in CCR (including death after SCT in first CR)b 20 (0) (9.6) 9 (3) (10.8) 18 (5) (9.2) 14 (3) (5.9)
Relapse (cumulative incidence) ND ND ND 36.4 ± 3.7
Secondary malignancies ND ND ND 0 (0)
Total group
pSurvival (5 years)
33 ± 3 38 ± 5 53 ± 5 63.1 ± 3.3
Total group
pEFS (5 years)
32 ± 3 36 ± 5 47 ± 5 51.8 ± 3.4
SR pEFS (5 years) NA 37 ± 8 62 ± 7 55.0 ± 6.6
HR pEFS (5 years) NA 41 ± 8 33 ± 7 50.6 ± 4.0
AML-BFM acute myeloid leukemia-Berlin–Frankfurt–Munster, AML-PPLLSG acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group, CR 
complete remission,CCR continous complete remission, HSCT hematopoietic stem cell transplantation, NA not applicable, ND non defined
aPercentage is given for patients with data (n/total)
bThe values in second parenthesis denotes percentage
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with translocation t(8;21) in comparison with children 
without this genetic rearrangement (Figs. 6 and 7), which 
is consistent with other studies [16]. This observation 
underlies the upcoming proposal of the AML-BFM Study 
Group for AML with t(8;21), which involves augmentation 
of induction therapy by introduction of the HAM cycle.
The treatment of pediatric AML needs further improve-
ment. Studies on biology of AML are needed to explore 
genetic abnormalities, which could be aimed for new 
targeted therapies [15, 26–28]. Introduction of targeted 
treatment modalities could allow a better stratification of 
patients, and use of more individualized therapies may 
lead to further improvements of treatment outcomes. 
The new treatment protocols for children with AML are 
expected to improve the treatment results and decrease 
the late side effect rates [13, 14, 29, 30]. However, fur-
ther progress in AML therapy seems possible because of 
continued cooperation of oncology centers within large 
international study groups.
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